A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors

The European Medicines Agency Review of Eribulin for the Treatment of Patients with Locally Advanced or Metastatic Breast Cancer: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use

(2012) E. Pean et al.   CLINICAL CANCER RESEARCH

Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole

(2012) L. A. Devriese et al.   INVESTIGATIONAL NEW DRUGS

Prospective evaluation of corrected QT intervals and arrhythmias after exposure to epirubicin, cyclophosphamide, and 5-fluorouracil in women with breast cancer

(2011) K. Kitagawa et al.   ANNALS OF ONCOLOGY

Eribulin mesylate in patients with refractory cancers: a Phase I study

(2011) Toru Mukohara et al.   INVESTIGATIONAL NEW DRUGS

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

(2011) Javier Cortes et al.   LANCET

Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine

(2010) Javier Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Creation of a Knowledge Management System for QT Analyses

(2010) Christoffer W. Tornøe et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Gender disparity in cardiac electrophysiology: Implications for cardiac safety pharmacology

(2010) M.K.B. Jonsson et al.   PHARMACOLOGY & THERAPEUTICS

Assessing proarrhythmic potential of drugs when optimal studies are infeasible

(2009) Edwin P. Rock et al.   AMERICAN HEART JOURNAL

Eribulin Binds at Microtubule Ends to a Single Site on Tubulin To Suppress Dynamic Instability

(2009) Jennifer A. Smith et al.   BIOCHEMISTRY

The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance

(2009) B Darpo   BRITISH JOURNAL OF PHARMACOLOGY

Evolving Approaches to Metastatic Breast Cancer Previously Treated with Anthracyclines and Taxanes

(2009) Conleth G. Murphy et al.   Clinical Breast Cancer

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

(2009) S. Goel et al.   CLINICAL CANCER RESEARCH

Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors

(2009) A. R. Tan et al.   CLINICAL CANCER RESEARCH

Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2009) Linda T. Vahdat et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase

(2008) T. Okouneva et al.   MOLECULAR CANCER THERAPEUTICS